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The disappointing results of long-term survival among patients with
non-small cell lung cancer (NSCLC) may reflect the lack of knowl-
edge of the ways in which molecular abnormalities of neoplastic
cells affect responsiveness to anticancer therapy. Remarkable ad-
vances in the understanding of NSCLC cancer biology have been
made over the past decade, including the discovery of critical
mutations in oncogenes (i.e., mutation of K-Ras and c-myc gene), as
well as the loss of tumor-suppressor genes, such as TP53, 16INK4,
or Rb. The future challenge of NSCLC chemotherapy relies on the
identification of molecular markers that are predictive of drug
sensitivity and help in the selection of chemotherapeutic agents best
suited to the individual patient. Other intriguing issues will be the
identification of the optimal drug sequence in combination regimens,
as well as polymorphisms of genes involved in severe toxicities.
(J Thorac Oncol. 2007;2: Suppl 1, 27–30)
POTENTIAL ROLE OF PHARMACOGENETICS IN
THERAPEUTIC DECISION
Disease stage, performance status, age, and comorbid-
ity could be useful in predicting patient prognosis in early-
stage NSCLC.1 Mediastinal lymph node involvement and
number of metastatic lymph nodes are important adverse
prognostic factors in surgically treated stage IIIA NSCLC.2
Moreover, there is a significant difference in survival when
the visceral pleura is invaded. However, clinical outcome
might be poor even for patients with early-stage NSCLC.3
Gene expression profile was studied as a predictor of risk of
recurrence among patients with early-stage NSCLC. It was
also found that the lung metagene model predicted recurrence
for individual patients significantly better than clinical prog-
nostic factors and that it was consistent across all early stages
of NSCLC.4
To date, clinical research has defined both adjuvant
treatment and chemotherapy for advanced-stage NSCLC,
especially platinum-based doublets, but future studies will
investigate the potential of choosing treatment on the basis of
mutations or altered expression of critical genes involved in
cell growth dysregulation. Moreover, predictive markers are
also emerging for molecular targeted agents. In this regard,
endothelial growth factor receptor (EGFR) mutations seem to
be promising markers to predict the benefit of EGFR inhib-
itors such as gefitinib and erlotinib. Therefore, the next step
will be the integration of the best pharmacogenetic marker in
prospective trials, using both conventional cytotoxic drugs
and new targeted treatments.
MOLECULAR DETERMINANTS RELATED TO
DRUG SENSITIVITY AND RESISTANCE
Examples on how genetics might affect drug response
are offered by platinum compounds, which inhibit cell pro-
liferation by irreversibly damaging DNA through the forma-
tion of intra- and interstrand cross-links. Drug resistance
occurs mostly because of detoxification or efficient repair of
damaged DNA by the numerous members of the nucleotide
excision repair (NER) system, including the endonuclease
excision repair cross-complementing 1 (ERCC1). In vitro stud-
ies demonstrated that up-regulation of ERCC1 is associated with
cisplatin resistance,5 and clinical studies demonstrated that re-
sponse and survival of patients with advanced NSCLC improved
in the presence of low ERCC1 expression.6
Moreover, data suggest that polymorphisms of ERCC1
Asn118Asn (CT), ERCC2 Lys751Gln (AC), and Asp
312Asn (GA) may be associated with clinical outcome. In
particular, among patients with NSCLC treated with cispla-
tin-combination chemotherapy, median survival time for pa-
tients showing the C/C genotype of codon 118 in ERCC1 was
486 days, significantly longer than for patients with genotype
T/T or C/T (281 days).7 Similar results were observed in
docetaxel/cisplatin-treated patients with NSCLC.8 Median
survival was 9.67 months for patients with ERCC1 118 C/T,
9.74 months for patients with T/T, and not reached for
patients with C/C genotype. Significant differences in time to
progression were also observed according to the ERCC1 118
genotype. However, in these studies, polymorphisms of
codons 751 and 312 in the ERCC2 gene did not affect patient
survival, and no significant correlation was observed between
ERCC2 genotype and objective response in a previous study
of patients with gemcitabine/cisplatin-treated locally ad-
vanced NSCLC.9 In contrast, recent research on patients with
stage IIIA-IV NSCLC reported that individuals with the 312
wild-type genotype (Asp/Asp) had a median survival of 16.3
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months, quite similar to the survival of 15.2 months in
subjects with heterozygous genotype, whereas those with the
homozygous variant (Asn/Asn) had a median survival time of
6.6 months. Similarly, patients with the 751 wild-type geno-
type (Arg/Arg) had a median survival of 17.3 months,
whereas individuals with the variant genotype (Gln/Gln) had
a median survival of 7.7 months. Finally, analysis of combi-
nations of variant alleles across both polymorphisms demon-
strated that a greater number of variant alleles was associated
with decreasing overall survival.10 Others authors used im-
munohistochemical analysis to determine the expression of
ERCC1 protein in surgical specimens of NSCLC in patients
enrolled in a clinical trial of adjuvant cisplatin-based chemo-
therapy. They found that patients with completely resected
NSCLC and ERCC1-negative tumors seemed to benefit from
adjuvant cisplatin-based chemotherapy, whereas patients
with ERCC1-positive tumors did not.11
Other DNA repair defects conferring cisplatin resis-
tance in vitro and in vivo may result from mutation or
methylation-mediated silencing of the mismatch repair genes
hMLH-1, hMSH-2, and hPMS-2. Similarly, the high mobility
group 1 (HMG1) protein, which is involved in DNA replication
and repair, was overexpressed in cisplatin-resistant cells.12
Finally, the Breast Cancer Gene 1 (BRCA1) also plays an
important role in DNA damage repair, and increased levels of
BRCA1 have been observed in cisplatin-resistant cells. In-
deed, antisense inhibition of BRCA1 increased sensitivity to
cisplatin and apoptosis induction.13
Mechanisms of resistance also involve decreased intra-
cellular accumulation of cisplatin because of an outward
efflux through the plasma membrane by multidrug resistance
protein 2 (MRP2) and increased detoxification associated
with glutathione acetyl-S-transferase (GSTP1) overexpres-
sion. However, there were no differences in clinical outcome
among patients with NSCLC treated with cisplatin/gemcitab-
ine, vinorelbine/cisplatin, or paclitaxel/carboplatin according
to GSTP1 transcript levels in the pretreatment biopsies.14
Single-arm and randomized gemcitabine phase II stud-
ies demonstrated meaningful response rates in more than 20%
of patients with NSCLC. Gemcitabine is carried into the cells
mostly by human equilibrative (hENT) and concentrative
(hCNT) nucleoside transporters. hENT1 levels were signifi-
cantly correlated with the IC50 values for gemcitabine in
NSCLC cell lines,15 and the modulation of hENT1 expression
induced by TS inhibitors may represent a new way of explor-
ing effective modalities for the treatment of lung cancer.
Following cell uptake, gemcitabine is phosphorylated
to its active diphosphate (dFdCDP) and triphosphate
(dFdCTP) metabolites that respectively inhibit ribonucleotide
reductase (RR) and DNA synthesis. Deoxycytidine kinase
(dCK) is the rate-limiting enzyme in the biotransformation of
nucleoside analogs, and several studies have suggested that
dCK is a limiting factor for gemcitabine activity because its
deficiency is critically involved in acquired resistance in vitro
models of lung cancer. Moreover, the pretreatment dCK
expression level could be used as a predictive parameter of
tumor sensitivity; indeed, a clear correlation has been shown
between dCK activity and gemcitabine sensitivity in tumor
xenografts.16 The crucial role of dCK was confirmed by the
marked reduction of gemcitabine cytotoxicity against NSCLC
cells using the natural substrate 2=-deoxycytidine, whereas
transcriptome analysis suggests that the synergistic interac-
tion with pemetrexed against NSCLC cells may be facilitated
by the increase of dCK expression. Indeed, as an inhibitor of
de novo purine biosynthesis, pemetrexed may enhance the
expression of enzymes involved in salvage nucleoside path-
ways, including dCK, as a compensatory mechanism. This
result is in agreement with previous studies, which indicated
that several chemotherapeutic agents, such as nucleoside
analogs, etoposide, and topotecan, had a stimulatory effect on
dCK.17 These findings may have implications for the rational
design of drug regimens incorporating gemcitabine and other
agents modulating dCK activity for the treatment of lung
cancer. Indeed, the evidence of preclinical sequence-depen-
dent synergism prompted a three-arm randomized phase II
study of pemetrexed plus gemcitabine as frontline therapy for
advanced NSCLC, and preliminary efficacy and toxicity data
indicated that pemetrexed followed by gemcitabine on Day 1
was the optimal schedule.18
The amount of phosphorylated metabolites of gemcit-
abine may be reduced by cellular 5=-nucleotidase (5=-NT),
whereas gemcitabine itself is inactivated by deamination by
cytidine deaminase (CDA); high expression of these catabolic
enzymes has been found in tumor cell lines resistant to
nucleoside analogs and gemcitabine. A recent immunohisto-
chemical study of tissues from patients with treatment-naı¨ve
locally advanced and metastatic NSCLC showed that 5=-NT
is an independent prognostic factor in gemcitabine-treated
patients. Indeed, patients with low levels of 5=-NT expression
had worse overall survival than patients with higher expres-
sion (6 and 11 months, respectively).19
A recent clinical study reported that patients with
NSCLC with lower expression of RR1 significantly benefited
from gemcitabine/cisplatin neoadjuvant chemotherapy.20 Fi-
nally, RR1 promoter allelotypes RR37CC-RR524TT were
associated with overall and disease-free survival among pa-
tients with resected NSCLC.21
In advanced NSCLC, gemcitabine-cisplatin combina-
tion response rates range from 31% to 54%, with a median
survival time between 8.4 and 15.4 months and a 1-year
survival rate between 30% and 59%. ERCC1 antisense RNA
abrogates the cytotoxic synergism of gemcitabine with cis-
platin in human colon cancer cells that were proficient in
NER. Indeed, the down-regulation of the repair activity
significantly correlated with the reduction of the cytotoxic
synergism between gemcitabine and cisplatin. These findings
suggest that the ERCC1 mRNA levels used to predict cispla-
tin response could be higher when cisplatin is combined with
gemcitabine.
A meta-analysis reported that UFT was an effective drug
for adjuvant chemotherapy of NSCLC. UFT is a prodrug of the
antimetabolite 5-fluorouracil, whose active metabolite, 5-fluoro-
deoxyuridine monophosphate, suppresses the conversion of de-
oxyuridine monophosphate to deoxythymidine monophosphate
by forming a stable ternary complex with thymidylate synthase
(TS). A recent clinical study of patients with resectable NSCLC
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revealed that TS status was a significant prognostic factor among
patients with stage II or III NSCLC. Furthermore, in patients
with stage II or III NSCLC, the survival of UFT-treated patients
with TS-negative tumors was significantly better.22 Therefore,
the synergistic activity of the vinorelbine-UFT schedule against
in vitro and in vivo models of NSCLC may be attributed to
increased chemosensitivity to UFT caused by vinorelbine-in-
duced suppression of TS.23
Another enzyme that may play a crucial role in UFT
resistance is dihydropyrimidine dehydrogenase (DPD). An
immunohistochemical study of patients with resected stage I
NSCLC revealed that subjects with low-DPD tumors who
received UFT had a significantly better prognosis than those
who did not receive adjuvant treatment.24 Thus, although a
prospective study is needed to confirm the role of TS and
DPD expression as a predictor of UFT efficacy, assays of
DPD and TS expression may be used as indicators for the use
of this drug.
No differences in time to progression (TTP) were found
among gemcitabine/cisplatin, vinorelbine/cisplatin, and pac-
litaxel/carboplatin treatments among patients with advanced
NSCLC, suggesting the role of microtubule-interacting agents
in NSCLC adjuvant chemotherapy. A major mechanism of
resistance to these drugs is represented by the mutation or
overexpression of specific tubulin isotypes. In particular, the
amino acid residues 1-31 and 217-233 have a relevant role for
paclitaxel binding to the protein, and mutations near these
sites, such as Thr274Ile and Arg282Gln, may be associated
with a drug-resistant phenotype.25 Therefore, the mutational
and gene expression analysis of tubulin isotypes could be of
critical importance in assessing the sensitivity of cancer cells
toward taxanes.  tubulin class I mutation had been described
in patients with NSCLC 26 and was identified in 33% of
patients with NSCLC, none of whom had an objective re-
sponse to paclitaxel treatment.27 The up-regulation of III
isotype is another important marker of resistance, and high
concentrations of III-tubulin are associated with a decrease
in paclitaxel sensitivity in NSCLC cells. More recently, the
quantitative polymerase chain reaction analysis of -III-
tubulin expression in pretreatment biopsies showed that, in
the paclitaxel/carboplatin arm, patients with low -III-tubulin
levels had a better response, and there was a tendency toward
correlation between -III-tubulin expression levels and TTP.
Furthermore, -III-tubulin expression significantly influ-
enced TTP in the vinorelbine/cisplatin arm.14
CONCLUSIONS
Adjuvant chemotherapy proved to be a useful approach
in selected solid tumors. For patients with NSCLC, a reliable
method is required to determine which drugs have the poten-
tial to improve survival without severe toxicities. With a
better understanding of the molecular mechanisms of disease
and drug activity, new techniques may improve the detection
and validation of biomarkers, which mutation or expression
has been found to be linked to enhanced response to chemo-
therapy and therefore survival. Therefore, genetic analysis of
NSCLC specimens and analysis of surrogate tissues (i.e.,
blood) for predicting drug activity should facilitate the choice
of chemotherapy treatment and improve the prognosis of
patients.
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